prostate

Summary

Summary: A gland in males that surrounds the neck of the BLADDER and the URETHRA. It secretes a substance that liquefies coagulated semen. It is situated in the pelvic cavity behind the lower part of the PUBIC SYMPHYSIS, above the deep layer of the triangular ligament, and rests upon the RECTUM.

Top Publications

  1. pmc Cooperativity of TMPRSS2-ERG with PI3-kinase pathway activation in prostate oncogenesis
    Jennifer C King
    Memorial Sloan Kettering Cancer Center, New York, New York, USA
    Nat Genet 41:524-6. 2009
  2. ncbi MicroRNA expression profiling in prostate cancer
    Kati P Porkka
    Laboratory of Cancer Genetics, Institute of Medical Technology, University of Tampere and Tampere University Hospital, Tampere, Finland
    Cancer Res 67:6130-5. 2007
  3. pmc Aberrant ERG expression cooperates with loss of PTEN to promote cancer progression in the prostate
    Brett S Carver
    Cancer Biology and Genetics Program, Sloan Kettering Institute, New York, New York, USA
    Nat Genet 41:619-24. 2009
  4. pmc Radical prostatectomy versus observation for localized prostate cancer
    Timothy J Wilt
    Center for Chronic Disease Outcomes Research, Minneapolis Veterans Affairs VA Health Care System, and Section of General Medicine, University of Minnesota School of Medicine, Minneapolis, USA
    N Engl J Med 367:203-13. 2012
  5. pmc ETS factors reprogram the androgen receptor cistrome and prime prostate tumorigenesis in response to PTEN loss
    Yu Chen
    Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York, USA
    Nat Med 19:1023-9. 2013
  6. pmc SMAD4-dependent barrier constrains prostate cancer growth and metastatic progression
    Zhihu Ding
    Belfer Institute for Applied Cancer Science, Dana Farber Cancer Institute, Boston, Massachusetts 02115, USA
    Nature 470:269-73. 2011
  7. ncbi The influence of finasteride on the development of prostate cancer
    Ian M Thompson
    University of Texas Health Science Center, San Antonio, USA
    N Engl J Med 349:215-24. 2003
  8. pmc miR-183-96-182 cluster is overexpressed in prostate tissue and regulates zinc homeostasis in prostate cells
    Brittany L Mihelich
    Department of Pathology, University of Illinois, Chicago, Illinois 60612, USA
    J Biol Chem 286:44503-11. 2011
  9. pmc Germline mutations in HOXB13 and prostate-cancer risk
    Charles M Ewing
    Johns Hopkins University and the James Buchanan Brady Urological Institute, Baltimore, USA
    N Engl J Med 366:141-9. 2012
  10. pmc mTOR complex 2 is required for the development of prostate cancer induced by Pten loss in mice
    David A Guertin
    Whitehead Institute for Biomedical Research, Cambridge, MA 02142, USA
    Cancer Cell 15:148-59. 2009

Detail Information

Publications366 found, 100 shown here

  1. pmc Cooperativity of TMPRSS2-ERG with PI3-kinase pathway activation in prostate oncogenesis
    Jennifer C King
    Memorial Sloan Kettering Cancer Center, New York, New York, USA
    Nat Genet 41:524-6. 2009
    The TMPRSS2-ERG fusion, present in approximately 50% of prostate cancers, is less common in prostatic intraepithelial neoplasia (PIN), raising questions about whether TMPRSS2-ERG contributes to disease initiation...
  2. ncbi MicroRNA expression profiling in prostate cancer
    Kati P Porkka
    Laboratory of Cancer Genetics, Institute of Medical Technology, University of Tampere and Tampere University Hospital, Tampere, Finland
    Cancer Res 67:6130-5. 2007
    ..To identify the miRNA signature specific for prostate cancer, miRNA expression profiling of 6 prostate cancer cell lines, 9 prostate cancer xenografts samples, 4 ..
  3. pmc Aberrant ERG expression cooperates with loss of PTEN to promote cancer progression in the prostate
    Brett S Carver
    Cancer Biology and Genetics Program, Sloan Kettering Institute, New York, New York, USA
    Nat Genet 41:619-24. 2009
    Chromosomal translocations involving the ERG locus are frequent events in human prostate cancer pathogenesis; however, the biological role of aberrant ERG expression is controversial...
  4. pmc Radical prostatectomy versus observation for localized prostate cancer
    Timothy J Wilt
    Center for Chronic Disease Outcomes Research, Minneapolis Veterans Affairs VA Health Care System, and Section of General Medicine, University of Minnesota School of Medicine, Minneapolis, USA
    N Engl J Med 367:203-13. 2012
    The effectiveness of surgery versus observation for men with localized prostate cancer detected by means of prostate-specific antigen (PSA) testing is not known.
  5. pmc ETS factors reprogram the androgen receptor cistrome and prime prostate tumorigenesis in response to PTEN loss
    Yu Chen
    Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York, USA
    Nat Med 19:1023-9. 2013
    Studies of ETS-mediated prostate oncogenesis have been hampered by a lack of suitable experimental systems. Here we describe a new conditional mouse model that shows robust, homogenous ERG expression throughout the prostate...
  6. pmc SMAD4-dependent barrier constrains prostate cancer growth and metastatic progression
    Zhihu Ding
    Belfer Institute for Applied Cancer Science, Dana Farber Cancer Institute, Boston, Massachusetts 02115, USA
    Nature 470:269-73. 2011
    Effective clinical management of prostate cancer (PCA) has been challenged by significant intratumoural heterogeneity on the genomic and pathological levels and limited understanding of the genetic elements governing disease progression...
  7. ncbi The influence of finasteride on the development of prostate cancer
    Ian M Thompson
    University of Texas Health Science Center, San Antonio, USA
    N Engl J Med 349:215-24. 2003
    Androgens are involved in the development of prostate cancer...
  8. pmc miR-183-96-182 cluster is overexpressed in prostate tissue and regulates zinc homeostasis in prostate cells
    Brittany L Mihelich
    Department of Pathology, University of Illinois, Chicago, Illinois 60612, USA
    J Biol Chem 286:44503-11. 2011
    Decreased zinc levels are a hallmark of prostate cancer tumors as zinc uniquely concentrates in healthy prostate tissue...
  9. pmc Germline mutations in HOXB13 and prostate-cancer risk
    Charles M Ewing
    Johns Hopkins University and the James Buchanan Brady Urological Institute, Baltimore, USA
    N Engl J Med 366:141-9. 2012
    Family history is a significant risk factor for prostate cancer, although the molecular basis for this association is poorly understood...
  10. pmc mTOR complex 2 is required for the development of prostate cancer induced by Pten loss in mice
    David A Guertin
    Whitehead Institute for Biomedical Research, Cambridge, MA 02142, USA
    Cancer Cell 15:148-59. 2009
    ..Here, we show that transformed human prostate epithelial cells lacking PTEN require mTORC2 to form tumors when injected into nude mice...
  11. ncbi Androgen receptor in prostate cancer
    Cynthia A Heinlein
    George Whipple Laboratory for Cancer Research, Department of Pathology, University of Rochester, Rochester, NY 14642, USA
    Endocr Rev 25:276-308. 2004
    The normal development and maintenance of the prostate is dependent on androgen acting through the androgen receptor (AR). AR remains important in the development and progression of prostate cancer...
  12. pmc Role of the TMPRSS2-ERG gene fusion in prostate cancer
    Scott A Tomlins
    Michigan Center for Translational Pathology, Department of Pathology, University of Michigan Medical School, Ann Arbor, MI 48109, USA
    Neoplasia 10:177-88. 2008
    TMPRSS2-ERG gene fusions are the predominant molecular subtype of prostate cancer. Here, we explored the role of TMPRSS2-ERG gene fusion product using in vitro and in vivo model systems...
  13. pmc Prostate stem cell antigen: a cell surface marker overexpressed in prostate cancer
    R E Reiter
    Department of Urology, University of California, Los Angeles, CA 90095, USA
    Proc Natl Acad Sci U S A 95:1735-40. 1998
    ..antigens is critical to the development of new diagnostic and therapeutic modalities for the management of prostate cancer...
  14. ncbi Gene expression alterations in prostate cancer predicting tumor aggression and preceding development of malignancy
    Yan Ping Yu
    University of Pittsburgh Cancer Institute and Department of Pathology, University of Pittsburgh, 3550 Terrace Street, Pittsburgh, PA 15261, USA
    J Clin Oncol 22:2790-9. 2004
    The incidence of prostate cancer is frequent, occurring in almost one-third of men older than 45 years. Only a fraction of the cases reach the stages displaying clinical significance...
  15. ncbi Autoantibody signatures in prostate cancer
    Xiaoju Wang
    Department of Pathology, University of Michigan Medical School, Ann Arbor, MI 48109, USA
    N Engl J Med 353:1224-35. 2005
    New biomarkers, such as autoantibody signatures, may improve the early detection of prostate cancer.
  16. pmc Identification of a cell of origin for human prostate cancer
    Andrew S Goldstein
    Molecular Biology Institute, University of California, Los Angeles UCLA, Los Angeles, CA 90095, USA
    Science 329:568-71. 2010
    Luminal cells are believed to be the cells of origin for human prostate cancer, because the disease is characterized by luminal cell expansion and the absence of basal cells...
  17. doi Diagnostic and prognostic signatures from the small non-coding RNA transcriptome in prostate cancer
    E S Martens-Uzunova
    Department of Urology, Josephine Nefkens Institute, Erasmus MC, Rotterdam, The Netherlands
    Oncogene 31:978-91. 2012
    b>Prostate cancer (PCa) is the most frequent male malignancy and the second most common cause of cancer-related death in Western countries. Current clinical and pathological methods are limited in the prediction of postoperative outcome...
  18. doi Alterations in beta-catenin expression and localization in prostate cancer
    Hayley C Whitaker
    Uro Oncology Research Group, Cancer Research UK Cambridge Research Institute, Li Ka Shing Centre, Robinson Way, Cambridge, UK
    Prostate 68:1196-205. 2008
    Wnt signaling is thought to be important in prostate cancer, in part because proteins such as beta-catenin can also affect androgen receptor signaling...
  19. doi MiR-221 expression affects invasion potential of human prostate carcinoma cell lines by targeting DVL2
    Chang Zheng
    Department of Urology, General Hospital of Jinan Military Command, 25 Shifan Road, 250031 Jinan, China
    Med Oncol 29:815-22. 2012
    The aim of this study is to evaluate the effect of the variation of miR-221 on the prostate cancer cells' NE differentiation and invasive function and to examine the function of miR-221 in plasma as a blood-based miRNA biomarker candidate ..
  20. ncbi CD133, a novel marker for human prostatic epithelial stem cells
    Gavin D Richardson
    Prostate Research Group, Surgical Oncology, Medical School, Framlington Place, University of Newcastle upon Tyne, Newcastle upon Tyne, NE2 4HH, UK
    J Cell Sci 117:3539-45. 2004
    ..self-renewal and differentiation properties, which may represent a major target for genetic damage leading to prostate cancer and benign prostatic hyperplasia...
  21. ncbi mTOR inhibition reverses Akt-dependent prostate intraepithelial neoplasia through regulation of apoptotic and HIF-1-dependent pathways
    Pradip K Majumder
    Department of Medical Oncology, Dana Farber Cancer Institute, and Department of Medicine, Brigham and Women s Hospital, Harvard Medical School, Boston, Massachusetts 02115, USA
    Nat Med 10:594-601. 2004
    ..mTOR inhibition induced apoptosis of epithelial cells and the complete reversal of a neoplastic phenotype in the prostate of mice expressing human AKT1 in the ventral prostate...
  22. doi Effect of dutasteride on the risk of prostate cancer
    Gerald L Andriole
    Division of Urology, Washington University School of Medicine in St Louis, St Louis, MO 63110, USA
    N Engl J Med 362:1192-202. 2010
    We conducted a study to determine whether dutasteride reduces the risk of incident prostate cancer, as detected on biopsy, among men who are at increased risk for the disease.
  23. pmc Prostate cancer and inflammation: the evidence
    Karen S Sfanos
    Department of Pathology, The Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD, USA
    Histopathology 60:199-215. 2012
    ..aim of this review is to summarize the current literature on the evidence for a role for chronic inflammation in prostate cancer aetiology, with a specific focus on recent advances regarding the following: (i) potential stimuli for ..
  24. pmc Lineage analysis of basal epithelial cells reveals their unexpected plasticity and supports a cell-of-origin model for prostate cancer heterogeneity
    Zhu A Wang
    Department of Medicine, Columbia University College of Physicians and Surgeons, New York, New York 10032, USA
    Nat Cell Biol 15:274-83. 2013
    ..We now show that initiation of prostate tumours in basal or luminal epithelial cells in mouse models results in tumours with distinct molecular ..
  25. doi A prospective phase III randomized trial of hypofractionation versus conventional fractionation in patients with high-risk prostate cancer
    Giorgio Arcangeli
    Department of Radiotherapy, Regina Elena National Cancer Institute, Rome, Italy
    Int J Radiat Oncol Biol Phys 78:11-8. 2010
    To compare the toxicity and efficacy of hypofractionated (62 Gy/20 fractions/5 weeks, 4 fractions per week) vs. conventional fractionation radiotherapy (80 Gy/40 fractions/8 weeks) in patients with high-risk prostate cancer.
  26. ncbi Androgen responsive adult human prostatic epithelial cell lines immortalized by human papillomavirus 18
    D Bello
    Department of Medicine, Michigan State University, East Lansing 48824 1312, USA
    Carcinogenesis 18:1215-23. 1997
    b>Prostate cancer and benign tumors of the prostate are the two most common neoplastic diseases in men in the United States, however, research on their causes and treatment has been slow because of the difficulty in obtaining fresh samples ..
  27. pmc TMPRSS2-ERG -specific transcriptional modulation is associated with prostate cancer biomarkers and TGF-β signaling
    Jan C Brase
    Unit Cancer Genome Research, Division of Molecular Genetics, German Cancer Research Center and National Center for Tumor Diseases, Im Neuenheimer Feld 460, 69120 Heidelberg, Germany
    BMC Cancer 11:507. 2011
    TMPRSS2-ERG gene fusions occur in about 50% of all prostate cancer cases and represent promising markers for molecular subtyping...
  28. doi Magnetic resonance imaging guided prostate biopsy in men with repeat negative biopsies and increased prostate specific antigen
    Thomas Hambrock
    University Medical Centre St Radboud, Nijmegen, The Netherlands
    J Urol 183:520-7. 2010
    Undetected cancer in repeat transrectal ultrasound guided prostate biopsies in patients with increased prostate specific antigen greater than 4 ng/ml is a considerable concern...
  29. doi Screening and prostate-cancer mortality in a randomized European study
    Fritz H Schroder
    Department of Urology, Erasmus Medical Center, Rotterdam, The Netherlands
    N Engl J Med 360:1320-8. 2009
    The European Randomized Study of Screening for Prostate Cancer was initiated in the early 1990s to evaluate the effect of screening with prostate-specific-antigen (PSA) testing on death rates from prostate cancer.
  30. pmc No evidence of XMRV in prostate cancer cohorts in the Midwestern United States
    Toshie Sakuma
    Department of Molecular Medicine, Mayo Clinic, Rochester, MN 55905, USA
    Retrovirology 8:23. 2011
    Xenotropic murine leukemia virus (MLV)-related virus (XMRV) was initially identified in prostate cancer (PCa) tissue, particularly in the prostatic stromal fibroblasts, of patients homozygous for the RNASEL R462Q mutation...
  31. ncbi Prostate cancer
    William G Nelson
    Department of Oncology, Johns Hopkins University School of Medicine, Baltimore, USA
    N Engl J Med 349:366-81. 2003
  32. ncbi DD3: a new prostate-specific gene, highly overexpressed in prostate cancer
    M J Bussemakers
    Urology Research Laboratory, University Hospital Nijmegen, The Netherlands
    Cancer Res 59:5975-9. 1999
    b>Prostate cancer is the most commonly diagnosed malignancy and the second leading cause of cancer-related deaths in the Western male population...
  33. pmc Dysregulation of circulating microRNAs and prediction of aggressive prostate cancer
    Jing Shen
    Department of Environmental Health Sciences, Mailman School of Public Health, Columbia University Medical Center, New York, New York, USA
    Prostate 72:1469-77. 2012
    It is becoming increasingly evident that microRNAs (miRNAs) are associated with the development and progression of prostate cancer (PCa).
  34. pmc β-catenin is required for prostate development and cooperates with Pten loss to drive invasive carcinoma
    Jeffrey C Francis
    Division of Cancer Biology, Institute of Cancer Research, London, United Kingdom
    PLoS Genet 9:e1003180. 2013
    b>Prostate cancer is a major cause of male death in the Western world, but few frequent genetic alterations that drive prostate cancer initiation and progression have been identified...
  35. pmc Metformin targets c-MYC oncogene to prevent prostate cancer
    Tunde Akinyeke
    Department of Basic Science and Craniofacial Biology, New York University College of Dentistry, New York, NY 10010 4086, USA
    Carcinogenesis 34:2823-32. 2013
    b>Prostate cancer (PCa) is the second leading cause of cancer-related death in American men and many PCa patients develop skeletal metastasis. Current treatment modalities for metastatic PCa are mostly palliative with poor prognosis...
  36. pmc Multiparametric magnetic resonance imaging and ultrasound fusion biopsy detect prostate cancer in patients with prior negative transrectal ultrasound biopsies
    Srinivas Vourganti
    Urologic Oncology Branch, National Cancer Institute, National Institutes of Health, Bethesda, Maryland20892 1210, USA
    J Urol 188:2152-7. 2012
    ..transrectal ultrasound biopsies and a persistent clinical suspicion are at risk for occult but significant prostate cancer...
  37. pmc miR-205 regulates basement membrane deposition in human prostate: implications for cancer development
    P Gandellini
    Department of Experimental Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy
    Cell Death Differ 19:1750-60. 2012
    The basement membrane (BM) is a layer of specialized extracellular matrix that surrounds normal prostate glands and preserves tissue integrity...
  38. pmc Molecular pathogenesis and progression of prostate cancer
    Randy Schrecengost
    Department of Cancer Biology, Thomas Jefferson University, Philadelphia, PA 19107, USA
    Semin Oncol 40:244-58. 2013
    b>Prostate cancer (PCa) is the most commonly diagnosed noncutaneous malignancy and second leading cause of cancer-related deaths in US males. Clinically, locally confined disease is treated surgically and/or with radiation therapy...
  39. pmc The reactive stroma microenvironment and prostate cancer progression
    David A Barron
    Department of Molecular and Cellular Biology, Baylor College of Medicine, Houston, TX 77030, USA
    Endocr Relat Cancer 19:R187-204. 2012
    Reactive stroma initiates during early prostate cancer development and coevolves with prostate cancer progression...
  40. doi Clinical-pathologic correlation between transperineal mapping biopsies of the prostate and three-dimensional reconstruction of prostatectomy specimens
    E David Crawford
    Division of Urology, University of Colorado, Anschutz Medical Campus, Aurora, CO, USA
    Prostate 73:778-87. 2013
    Extended transrectal ultrasound guided biopsies (TRUSB) of the prostate may not accurately convey true morphometric information and Gleason score (GS) of prostate cancer (PCa) and the clinical use of template-guided (5-mm grid) ..
  41. pmc Tissue slice grafts: an in vivo model of human prostate androgen signaling
    Hongjuan Zhao
    Department of Urology, Stanford University School of Medicine, Stanford, CA 94305 5118, USA
    Am J Pathol 177:229-39. 2010
    ..This new in vivo model not only allows analysis of approximately all of the cell types present in prostate cancer within an intact tissue microenvironment, but also provides a more accurate assessment of the effects of ..
  42. pmc Pten dose dictates cancer progression in the prostate
    Lloyd C Trotman
    Molecular Biology Program, Memorial Sloan Kettering Cancer Center, Sloan Kettering Institute, New York, New York, USA
    PLoS Biol 1:E59. 2003
    Complete inactivation of the PTEN tumor suppressor gene is extremely common in advanced cancer, including prostate cancer (CaP). However, one PTEN allele is already lost in the vast majority of CaPs at presentation...
  43. doi Acute and late toxicity in a randomized trial of conventional versus hypofractionated three-dimensional conformal radiotherapy for prostate cancer
    Giorgio Arcangeli
    Department of Radiation Oncology, Regina Elena National Cancer Institute, Rome, Italy
    Int J Radiat Oncol Biol Phys 79:1013-21. 2011
    To compare the toxicity between hypofractionation vs. conventional fractionation schedules in patients with high-risk prostate cancer.
  44. ncbi Planning target margin calculations for prostate radiotherapy based on intrafraction and interfraction motion using four localization methods
    Chris Beltran
    Department of Radiation Oncology, Mayo Clinic College of Medicine, Rochester, MN, USA
    Int J Radiat Oncol Biol Phys 70:289-95. 2008
    To determine planning target volume (PTV) margins for prostate radiotherapy based on the internal margin (IM) (intrafractional motion) and the setup margin (SM) (interfractional motion) for four daily localization methods: skin marks (..
  45. pmc MicroRNA-145 is regulated by DNA methylation and p53 gene mutation in prostate cancer
    Seong O Suh
    Department of Urology, Veterans Affairs Medical Center and University of California at San Francisco, 4150 Clement Street, San Francisco, CA 94121, USA
    Carcinogenesis 32:772-8. 2011
    MiR-145 is downregulated in various cancers including prostate cancer. However, the underlying mechanisms of miR-145 downregulation are not fully understood...
  46. pmc Antagonists of growth hormone-releasing hormone (GHRH) reduce prostate size in experimental benign prostatic hyperplasia
    Ferenc G Rick
    Veterans Affairs Medical Center, Miami, FL 33125, USA
    Proc Natl Acad Sci U S A 108:3755-60. 2011
    ..potent synthetic antagonists of GHRH strongly inhibit the growth of diverse experimental human tumors including prostate cancer by suppressing various tumoral growth factors...
  47. pmc Sulforaphane increases drug-mediated cytotoxicity toward cancer stem-like cells of pancreas and prostate
    Georgios Kallifatidis
    Molecular OncoSurgery, University of Heidelberg, Heidelberg, Germany
    Mol Ther 19:188-95. 2011
    ..Similarly, SF potentiated the drug effect in established prostate CSCs revealing that SF enhances drug cytotoxicity also in other tumor entities...
  48. ncbi Malignant transformation in a nontumorigenic human prostatic epithelial cell line
    S W Hayward
    Department of Urology, University of California San Francisco, San Francisco, CA 94143, USA
    Cancer Res 61:8135-42. 2001
    ..The cells continued to express SV40T antigen. These cell strains, which are all derived from a common nontumorigenic progenitor, represent a useful resource for examining genetic and phenotypic changes during carcinogenesis...
  49. pmc No detection of XMRV in blood samples and tissue sections from prostate cancer patients in Northern Europe
    Kristin Stieler
    Institute for Medical Microbiology and Virology, University Medical Center Hamburg Eppendorf, Hamburg, Germany
    PLoS ONE 6:e25592. 2011
    We recently published the rare detection of xenotropic murine leukemia virus-related virus (XMRV) (1/105) in prostate cancer (PCA) tissue of patients in Northern Europe by PCR...
  50. ncbi Operating characteristics of prostate-specific antigen in men with an initial PSA level of 3.0 ng/ml or lower
    Ian M Thompson
    Department of Urology, University of Texas Health Science Center at San Antonio, TX 78229, USA
    JAMA 294:66-70. 2005
    Three fourths of US men older than 50 years have been screened with prostate-specific antigen (PSA) for prostate cancer.
  51. doi Regression of castrate-recurrent prostate cancer by a small-molecule inhibitor of the amino-terminus domain of the androgen receptor
    Raymond J Andersen
    Chemistry and Earth and Ocean Sciences, University of British Columbia, 2036 Main Mall, Vancouver, BC, Canada V6T 1Z1
    Cancer Cell 17:535-46. 2010
    Castration-recurrent prostate cancer (CRPC) is suspected to depend on androgen receptor (AR). The AF-1 region in the amino-terminal domain (NTD) of AR contains most, if not all, of the transcriptional activity...
  52. pmc miR-21: an oncomir on strike in prostate cancer
    Marco Folini
    Department of Experimental Oncology and Molecular Medicine, Fondazione IRCCS Istituto Nazionale dei Tumori, Via Venezian, 1, Milan, 20133, Italy
    Mol Cancer 9:12. 2010
    ..However, scanty information is available concerning the relevance of miR-21 for prostate cancer...
  53. pmc Siah2-dependent concerted activity of HIF and FoxA2 regulates formation of neuroendocrine phenotype and neuroendocrine prostate tumors
    Jianfei Qi
    Signal Transduction Program, Sanford Burnham Medical Research Institute, La Jolla, CA 92037, USA
    Cancer Cell 18:23-38. 2010
    Neuroendocrine (NE) phenotype, seen in >30% of prostate adenocarcinomas (PCa), and NE prostate tumors are implicated in aggressive prostate cancer...
  54. doi Radical prostatectomy versus watchful waiting in early prostate cancer
    Anna Bill-Axelson
    Department of Urology, University Hospital, Uppsala, Sweden
    N Engl J Med 364:1708-17. 2011
    In 2008, we reported that radical prostatectomy, as compared with watchful waiting, reduces the rate of death from prostate cancer. After an additional 3 years of follow-up, we now report estimated 15-year results.
  55. doi Generation of a prostate from a single adult stem cell
    Kevin G Leong
    Department of Molecular Biology, Genentech, Inc, 1 DNA Way, South San Francisco, California 94080, USA
    Nature 456:804-8. 2008
    The existence of prostate stem cells (PSCs) was first postulated from the observation that normal prostate regeneration can occur after repeated cycles of androgen deprivation and replacement in rodents...
  56. doi American Cancer Society guideline for the early detection of prostate cancer: update 2010
    Andrew M D Wolf
    University of Virginia School of Medicine, Charlottesville, VA, USA
    CA Cancer J Clin 60:70-98. 2010
    In 2009, the American Cancer Society (ACS) Prostate Cancer Advisory Committee began the process of a complete update of recommendations for early prostate cancer detection...
  57. doi TMPRSS2-ERG fusion, a common genomic alteration in prostate cancer activates C-MYC and abrogates prostate epithelial differentiation
    C Sun
    Department of Surgery, Center for Prostate Disease Research, Uniformed Services University of the Health Sciences, Rockville, MD 20852, USA
    Oncogene 27:5348-53. 2008
    The high prevalence of TMPRSS2-ERG rearrangements ( approximately 60%) in prostate cancer (CaP) leads to androgenic induction of the ETS-related gene (ERG) expression...
  58. ncbi Pretreatment evaluation of prostate cancer: role of MR imaging and 1H MR spectroscopy
    Filip G Claus
    Department of Radiology, Memorial Sloan Kettering Cancer Center, 1275 York Ave, C278, New York, NY 10021, USA
    Radiographics 24:S167-80. 2004
    Magnetic resonance (MR) imaging and hydrogen 1 MR spectroscopy of the prostate gland are performed during the same examination with a conventional clinical MR unit...
  59. pmc Molecular characterization of neuroendocrine prostate cancer and identification of new drug targets
    Himisha Beltran
    Department of Medicine, Weill Cornell Medical College, New York, New York 10065, USA
    Cancer Discov 1:487-95. 2011
    Neuroendocrine prostate cancer (NEPC) is an aggressive subtype of prostate cancer that most commonly evolves from preexisting prostate adenocarcinoma (PCA)...
  60. doi High aldehyde dehydrogenase activity identifies tumor-initiating and metastasis-initiating cells in human prostate cancer
    Christel van den Hoogen
    Department of Urology, Leiden University Medical Center, Leiden, The Netherlands
    Cancer Res 70:5163-73. 2010
    Metastatic progression of advanced prostate cancer is a major clinical problem...
  61. ncbi Prostate cancer epidemiology
    Ann W Hsing
    Division of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, Maryland 20852 7234, USA
    Front Biosci 11:1388-413. 2006
    b>Prostate cancer is the most common non-skin cancer among men in most western populations, and it is the second leading cause of cancer death among U.S. men...
  62. pmc A comprehensive panel of three-dimensional models for studies of prostate cancer growth, invasion and drug responses
    Ville Härmä
    Medical Biotechnology Knowledge Centre, VTT Technical Research Centre of Finland, Turku, Finland
    PLoS ONE 5:e10431. 2010
    b>Prostate epithelial cells from both normal and cancer tissues, grown in three-dimensional (3D) culture as spheroids, represent promising in vitro models for the study of normal and cancer-relevant patterns of epithelial differentiation...
  63. ncbi SIRT1 is significantly elevated in mouse and human prostate cancer
    Derek M Huffman
    Division of Physiology and Metabolism, Department of Nutrition Sciences, University of Alabama at Birmingham, 1670 University Boulevard, Birmingham, AL 35294, USA
    Cancer Res 67:6612-8. 2007
    ..First, a transgenic mouse model of prostate cancer (transgenic adenocarcinoma of mouse prostate; TRAMP) was used to determine the role of energy balance on ..
  64. doi Kallikreins on steroids: structure, function, and hormonal regulation of prostate-specific antigen and the extended kallikrein locus
    Mitchell G Lawrence
    Australian Prostate Cancer Research Centre Queensland, Institute of Health and Biomedical Innovation, Queensland University of Technology, Brisbane, Australia
    Endocr Rev 31:407-46. 2010
    ..The kallikrein family is also emerging as a rich source of disease biomarkers with KLK3, commonly known as prostate-specific antigen, being the current serum biomarker for prostate cancer...
  65. doi Imaging mass spectrometry of a specific fragment of mitogen-activated protein kinase/extracellular signal-regulated kinase kinase kinase 2 discriminates cancer from uninvolved prostate tissue
    Lisa H Cazares
    Department of Microbiology and Molecular Cell Biology, Eastern Virginia Medical School, Norfolk, Virginia 23507, USA
    Clin Cancer Res 15:5541-51. 2009
    ..Direct profiling of proteins from tissue using matrix-assisted laser desorption/ionization imaging mass spectrometry has the potential to supplement morphology with underlying molecular detail...
  66. pmc The role of CD133 in normal human prostate stem cells and malignant cancer-initiating cells
    Donald J Vander Griend
    Chemical Therapeutics Program, The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, The Brady Urological Institute, and Department of Pathology, The Johns Hopkins University School of Medicine, Baltimore, Maryland 21231, USA
    Cancer Res 68:9703-11. 2008
    Resolving the specific cell of origin for prostate cancer is critical to define rational targets for therapeutic intervention and requires the isolation and characterization of both normal human prostate stem cells and prostate cancer-..
  67. ncbi TGF-beta signaling in fibroblasts modulates the oncogenic potential of adjacent epithelia
    Neil A Bhowmick
    Department of Cancer Biology, Vanderbilt University School of Medicine, Nashville, TN 37232, USA
    Science 303:848-51. 2004
    ..The loss of TGF-beta responsiveness in fibroblasts resulted in intraepithelial neoplasia in prostate and invasive squamous cell carcinoma of the forestomach, both associated with an increased abundance of stromal ..
  68. doi Increased expressions of cannabinoid receptor-1 and transient receptor potential vanilloid-1 in human prostate carcinoma
    Gabriella Czifra
    Department of Physiology, Medical and Health Science Center, Research Center for Molecular Medicine, University of Debrecen, Debrecen, Hungary
    J Cancer Res Clin Oncol 135:507-14. 2009
    Recently, functional cannabinoid receptor-1 (CB1) and vanilloid receptor-1 (TRPV1) have been described in human prostate and prostate cancer-derived cell lines where the activation of the receptors resulted in inhibition of cellular ..
  69. doi Mitochondrial DNA depletion in prostate epithelial cells promotes anoikis resistance and invasion through activation of PI3K/Akt2
    L Moro
    Institute of Biomembranes and Bioenergetics, National Research Council CNR, Bari, Italy
    Cell Death Differ 16:571-83. 2009
    Neoplastic transformation of prostate epithelium involves aberrant activation of anti-apoptotic and pro-invasive pathways triggered by multiple poorly understood genetic events...
  70. pmc Magnetic resonance imaging/ultrasound fusion guided prostate biopsy improves cancer detection following transrectal ultrasound biopsy and correlates with multiparametric magnetic resonance imaging
    Peter A Pinto
    Urologic Oncology Branch, Clinical Center and National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892 1210, USA
    J Urol 186:1281-5. 2011
    ..developed that fuses pre-biopsy magnetic resonance imaging with real-time transrectal ultrasound imaging to identify and biopsy lesions suspicious for prostate cancer. The cancer detection rates for the first 101 patients are reported.
  71. pmc ETV1 directs androgen metabolism and confers aggressive prostate cancer in targeted mice and patients
    Esther Baena
    Division of Hematology and Oncology, Boston Children s Hospital, Boston, Massachusetts 02115, USA
    Genes Dev 27:683-98. 2013
    ..from indolent disease and developing effective therapy for advanced disease are the major challenges in prostate cancer research...
  72. doi L-Mimosine blocks cell proliferation via upregulation of B-cell translocation gene 2 and N-myc downstream regulated gene 1 in prostate carcinoma cells
    Li Chuan Chung
    Department of Bioengineering, Tatung University, Taipei, Taiwan, Republic of China
    Am J Physiol Cell Physiol 302:C676-85. 2012
    ..We evaluated the molecular mechanisms of L-mimosine on cell cycle modulation in PC-3 and LNCaP prostate carcinoma cells...
  73. doi MiR-182 and miR-203 induce mesenchymal to epithelial transition and self-sufficiency of growth signals via repressing SNAI2 in prostate cells
    Yi Qu
    The Gade Institute, University of Bergen, Bergen, Norway
    Int J Cancer 133:544-55. 2013
    ..Here, we report the dual functions of miR-182 and miR-203 in our previously described prostate cell model...
  74. doi Combined multiparametric MRI and targeted biopsies improve anterior prostate cancer detection, staging, and grading
    Adil Ouzzane
    Department of Urology, CHU, University Lille, France
    Urology 78:1356-62. 2011
    To assess the efficacy of magnetic resonance imaging (MRI) in detection of suspicious anterior prostate lesions, and its role in staging and grading of anterior prostate cancer (APC).
  75. doi First evidence of sphingosine 1-phosphate lyase protein expression and activity downregulation in human neoplasm: implication for resistance to therapeutics in prostate cancer
    Leyre Brizuela
    CNRS, Institut de Pharmacologie et de Biologie Structurale, Universite de Toulouse, UPS, IPBS Toulouse Cedex 4, France
    Mol Cancer Ther 11:1841-51. 2012
    ..1-phosphate (S1P), a bioactive lipid associated with resistance to therapeutics in various cancers, including prostate adenocarcinoma...
  76. pmc An accurate prostate cancer prognosticator using a seven-gene signature plus Gleason score and taking cell type heterogeneity into account
    Xin Chen
    Department of Pathology and Laboratory Medicine, University of California Irvine, Irvine, California, USA
    PLoS ONE 7:e45178. 2012
    One of the major challenges in the development of prostate cancer prognostic biomarkers is the cellular heterogeneity in tissue samples...
  77. doi Standards of reporting for MRI-targeted biopsy studies (START) of the prostate: recommendations from an International Working Group
    Caroline M Moore
    Division of Surgical and Interventional Sciences, University College London, London, UK
    Eur Urol 64:544-52. 2013
    A systematic literature review of magnetic resonance imaging (MRI)-targeted prostate biopsy demonstrates poor adherence to the Standards for the Reporting of Diagnostic Accuracy (STARD) recommendations for the full and transparent ..
  78. pmc Tumor suppressor gene inactivation during cadmium-induced malignant transformation of human prostate cells correlates with overexpression of de novo DNA methyltransferase
    Lamia Benbrahim-Tallaa
    Laboratory of Comparative Carcinogenesis, National Cancer Institute at National Institute of Environmental Health Sciences, National Institutes of Health, Department of Health and Human Services, Research Triangle Park, North Carolina 27709, USA
    Environ Health Perspect 115:1454-9. 2007
    ..The typical pattern appears to involve reduced expression of maintenance DNA methyltransferase, DNMT1, inducing genomic hypomethylation, whereas increased expression of de novo DNMT3a or 3b causes gene-specific hypermethylation...
  79. pmc IL-6 promotes prostate tumorigenesis and progression through autocrine cross-activation of IGF-IR
    A Rojas
    Department of Medicine, University of Washington, Seattle, WA 98104, USA
    Oncogene 30:2345-55. 2011
    As an established mediator of inflammation, interleukin-6 (IL-6) is implicated to facilitate prostate cancer progression to androgen independence through transactivation of the androgen receptor...
  80. pmc Phase I study of noninvasive imaging of adenovirus-mediated gene expression in the human prostate
    Kenneth N Barton
    Department of Radiation Oncology, Henry Ford Health System, Detroit, Michigan 48202, USA
    Mol Ther 16:1761-9. 2008
    ..Men with clinically localized prostate cancer were administered an intraprostatic injection of a replication-competent adenovirus, Ad5-yCD/utTK(SR39)rep-..
  81. ncbi Regulation of apoptosis by a prostate-specific and prostate cancer-associated noncoding gene, PCGEM1
    Xiaoqin Fu
    Department of Surgery, Center for Prostate Disease Research CPDR, U S Military Cancer Institute, Uniformed Services University of the Health Sciences, Bethesda, MD 20852, USA
    DNA Cell Biol 25:135-41. 2006
    PCGEM1 is a prostate tissue-specific, and prostate cancer-associated noncoding RNA (ncRNA) gene...
  82. pmc Androgen receptor variants occur frequently in castration resistant prostate cancer metastases
    Xiaotun Zhang
    Department of Urology, University of Washington, Seattle, Washington, United States of America
    PLoS ONE 6:e27970. 2011
    Although androgens are depleted in castration resistant prostate cancer (CRPC), metastases still express nuclear androgen receptor (AR) and androgen regulated genes...
  83. pmc Structural and ultrastructural evidence for telocytes in prostate stroma
    Lara S Corradi
    Department of Biology, Institute of Biosciences, Humanities and Exact Sciences IBILCE, Univ Estadual Paulista UNESP, Sao Jose do Rio Preto, Sao Paulo, Brazil
    J Cell Mol Med 17:398-406. 2013
    The prostate comprises a glandular epithelium embedded within a fibromuscular stroma...
  84. ncbi Hormonal, cellular, and molecular control of prostatic development
    Paul C Marker
    Department of Anatomy, University of California San Francisco, San Francisco, CA 94143, USA
    Dev Biol 253:165-74. 2003
    The prostate is a male accessory sex gland found only in mammals that functions to produce a major fraction of seminal fluid...
  85. pmc Androgen receptor is causally involved in the homeostasis of the human prostate endothelial cell
    Alejandro Godoy
    Department of Urologic Oncology, Roswell Park Cancer Institute, Elm and Carlton Streets, Buffalo, New York 14263, USA
    Endocrinology 149:2959-69. 2008
    Androgen deprivation causes a reduction of blood flow in the prostate gland that precedes temporally apoptosis of the epithelium...
  86. pmc Low-calcium serum-free defined medium selects for growth of normal prostatic epithelial stem cells
    Ivan V Litvinov
    Chemical Therapeutics Program, The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, The Johns Hopkins University School of Medicine, Baltimore, MD 21231, USA
    Cancer Res 66:8598-607. 2006
    ..and the origin of nonimmortalized (PrEC) and immortalized (PZ-HPV7, CA-HPV10, RWPE-1, and 957E/hTERT) human prostate cell lines...
  87. ncbi High level of androgen receptor is associated with aggressive clinicopathologic features and decreased biochemical recurrence-free survival in prostate: cancer patients treated with radical prostatectomy
    Rile Li
    Department of Pathology, Baylor College of Medicine, Houston, TX 77030, USA
    Am J Surg Pathol 28:928-34. 2004
    b>Prostate cancer (PCa) is androgen dependent and is regulated by androgen/androgen receptor (AR) signaling pathway. However, the clinical significance of AR is in question...
  88. pmc Effect of anatomic motion on proton therapy dose distributions in prostate cancer treatment
    Xiaodong Zhang
    Department of Radiation Physics, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Int J Radiat Oncol Biol Phys 67:620-9. 2007
    To determine the dosimetric impact of interfraction anatomic movements in prostate cancer patients receiving proton therapy.
  89. doi Radiotherapy and short-term androgen deprivation for localized prostate cancer
    Christopher U Jones
    Radiological Associates of Sacramento, Sacramento, CA 95816, USA
    N Engl J Med 365:107-18. 2011
    It is not known whether short-term androgen-deprivation therapy (ADT) before and during radiotherapy improves cancer control and overall survival among patients with early, localized prostate adenocarcinoma.
  90. ncbi Identification and isolation of human prostate epithelial stem cells based on alpha(2)beta(1)-integrin expression
    A T Collins
    Prostate Research Group, Department of Surgery, The Medical School, University of Newcastle, Newcastle upon Tyne, NE2 4HH, UK
    J Cell Sci 114:3865-72. 2001
    ..We made use of the known association of stem cells with basement membranes to isolate prostate epithelial stem cells...
  91. ncbi Hormonal, cellular, and molecular regulation of normal and neoplastic prostatic development
    Gerald R Cunha
    Department of Anatomy, University of California, Box 0452, 513 Parnassus Avenue, San Francisco, CA 94143 0452, USA
    J Steroid Biochem Mol Biol 92:221-36. 2004
    This review on normal and neoplastic growth of the prostate emphasizes the importance of epithelial-mesenchymal/stromal interactions...
  92. pmc Detection of xenotropic murine leukemia virus-related virus in normal and tumor tissue of patients from the southern United States with prostate cancer is dependent on specific polymerase chain reaction conditions
    Bryan P Danielson
    Department of Molecular Virology and Microbiology, Baylor College of Medicine, Houston, Texas 77030, USA
    J Infect Dis 202:1470-7. 2010
    ..are questions regarding the prevalence of xenotropic murine leukemia virus-related virus (XMRV) in patients with prostate cancer and its association with the RNASEL R462Q polymorphism...
  93. ncbi Oxidative DNA damage in prostate cancer patients consuming tomato sauce-based entrees as a whole-food intervention
    L Chen
    Department of Human Nutrition, University of Illinois at Chicago, 60612, USA
    J Natl Cancer Inst 93:1872-9. 2001
    BACKGROUND: Human prostate tissues are vulnerable to oxidative DNA damage. The risk of prostate cancer is lower in men reporting higher consumption of tomato products, which contain high levels of the antioxidant lycopene...
  94. pmc Deep sequencing reveals distinct patterns of DNA methylation in prostate cancer
    Jung H Kim
    Michigan Center for Translational Pathology, University of Michigan Medical School, Ann Arbor, MI 48109, USA
    Genome Res 21:1028-41. 2011
    Beginning with precursor lesions, aberrant DNA methylation marks the entire spectrum of prostate cancer progression...
  95. pmc CD44+ CD24(-) prostate cells are early cancer progenitor/stem cells that provide a model for patients with poor prognosis
    E M Hurt
    Cancer Stem Cell Section, Laboratory of Cancer Prevention, Center for Cancer Research, National Cancer Institute at Frederick, National Institutes of Health, Frederick, MD 21702, USA
    Br J Cancer 98:756-65. 2008
    ..Using flow cytometry, we isolated a population of CD44+CD24(-) prostate cells that display stem cell characteristics as well as gene expression patterns that predict overall survival in ..
  96. pmc Four microRNAs promote prostate cell proliferation with regulation of PTEN and its downstream signals in vitro
    Ling Tian
    State Key Laboratory of Genetic Engineering and Institute of Genetics, School of Life Sciences, Fudan University, Shanghai, China Experimental Research Center and Cancer Center, Shanghai First People s Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, China
    PLoS ONE 8:e75885. 2013
    ..and tensin homologue (PTEN), as a tumor suppressor, plays vital roles in tumorigenesis and progression of prostate cancer. However, the mechanisms of PTEN regulation still need further investigation...
  97. doi Recurrent deletion of 3p13 targets multiple tumour suppressor genes and defines a distinct subgroup of aggressive ERG fusion-positive prostate cancers
    Antje Krohn
    Institute of Pathology, University Medical Centre Hamburg Eppendorf, Hamburg, Germany
    J Pathol 231:130-41. 2013
    Deletion of 3p13 has been reported from about 20% of prostate cancers. The clinical significance of this alteration and the tumour suppressor gene(s) driving the deletion remain to be identified...
  98. doi Screening for prostate cancer
    Dragan Ilic
    Department of Epidemiology and PreventiveMedicine, School of PublicHealth and PreventiveMedicine, MonashUniversity, Melbourne, Australia
    Cochrane Database Syst Rev 1:CD004720. 2013
    ..Screening for prostate cancer has generated considerable debate within the medical and broader community, as demonstrated by the varying ..
  99. doi Conditionally ablated Pten in prostate basal cells promotes basal-to-luminal differentiation and causes invasive prostate cancer in mice
    Tsai Ling Lu
    Department of Life Sciences and Institute of Genome Sciences, National Yang Ming University, Taipei, Taiwan
    Am J Pathol 182:975-91. 2013
    b>Prostate glands comprise two major epithelial cell types: luminal and basal. Luminal cells have long been considered the cellular origin of prostate cancer (CaP)...
  100. doi Multipotent and unipotent progenitors contribute to prostate postnatal development
    Marielle Ousset
    Universite Libre de Bruxelles ULB, IRIBHM, Brussels B 1070, Belgium
    Nat Cell Biol 14:1131-8. 2012
    The prostate is a glandular epithelium composed of basal, luminal and neuroendocrine cells that originate from the urogenital sinus during embryonic development. After birth, the prostate keeps developing until the end of puberty...
  101. pmc Doxycycline regulated induction of AKT in murine prostate drives proliferation independently of p27 cyclin dependent kinase inhibitor downregulation
    Hongyun Wang
    Hematology Oncology Division, Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts, United States of America
    PLoS ONE 7:e41330. 2012
    ..Transgenic mice with a probasin promoter controlled prostate specific reverse tetracycline transactivator (ARR2Pb-rtTA) were generated and used to achieve doxycycline ..

Research Grants78

  1. NIEHS SUPPORT OF THE AHS COHORT STUDY AT NCI
    Charles Knott; Fiscal Year: 2010
    ..and other chronic diseases is continuing and a number of manuscripts focusing on cancer incidence overall, prostate cancer, colorectal cancer, pancreatic cancer, lunch cancer, breast cancer, and melanoma are now published...
  2. THE AGRICULTURAL HEALTH STUDY - FIELD STATIONS
    Charles Lynch; Fiscal Year: 2010
    ..and other chronic diseases is continuing and a number of manuscripts focusing on cancer incidence overall, prostate cancer, colorectal cancer, pancreatic cancer, lunch cancer, breast cancer, and melanoma are now published...
  3. Role of the Y-Located TSPY Gene in Human Oncogenesis
    Yun Fai Chris Lau; Fiscal Year: 2013
    ..and plays key roles in the initiation and/or progression of gonadoblastoma, testicular germ cell tumors, prostate cancer, and sexual dimorphic cancers, such as hepatocellular carcinoma...
  4. Vitamin D3, Interference with Androgen Signal and Inhibition of Prostate Cancer
    Bandana Chatterjee; Fiscal Year: 2013
    DESCRIPTION (provided by applicant): Anti-proliferation activity of 1,25-(OH)2vitamin D3 (D3) in prostate cancer cells highlights the therapeutic potential of D3/D3 analogs...
  5. FASEB SRC on Lysophospholipd Mediators in Health and Disease
    Julie D Saba; Fiscal Year: 2011
    ..and radiation resistance, tumor angiogenesis, and progression of many cancer types including ovarian, breast, prostate, thyroid, colon, brain and hematological malignancies...
  6. Prostate, Lung, Colorectal and Ovarian (PLCO) Screening Trial
    Mona Fouad; Fiscal Year: 2013
    The Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial is a large scale, randomized controlled trial to determine whether certain screening tests will reduce the number of deaths from these cancers...
  7. Prostate, Lung, Colorectal and Ovarian (PLCO) Screening Trial
    BARBARA O'BRIEN; Fiscal Year: 2013
    I. The Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial is a large scale, randomized controlled trial to determine whether certain screening tests will reduce the number of deaths from these cancers...
  8. Development of VN/14-1 and Related Analogs for Breast Cancer Therapy
    VINCENT COLLINS OFUKA NJAR; Fiscal Year: 2013
    ..of vitamin A (retinol) and its active metabolite, all-trans retinoic acid (ATRA) on the incidence of breast and prostate cancers in humans...
  9. Response to and signals of caloric restriction and intermittent feeding regimens
    MARC KOPEL HELLERSTEIN; Fiscal Year: 2010
    ..Biomarkers that respond to CR and certain mADF regimens include global cell proliferation (mammary, prostate, skin, liver, lymphocytes), adipose tissue dynamics and fat distribution, insulin sensitivity, and vascular ..
  10. Metabolic Engineering of Bacteria for Cancer Immunotherapy by Gamma Delta T Cells
    Craig T Morita; Fiscal Year: 2013
    ..More people in the US die of lung cancer than breast, colon, kidney, and prostate cancers combined...
  11. Role of IKK in NSCLC: Modulation of SMRT and NF-kappaB
    Marty W Mayo; Fiscal Year: 2012
    Lung cancer is the number one cancer killer in the United States, exceeding breast, colorectal, prostate, and melanoma malignancies combined...
  12. Prostate cancer chemoprevention by penta-galloyl-glucose
    Junxuan Lu; Fiscal Year: 2013
    ..is to develop Oriental herbal compound 1,2,3,4,6-penta-O-galloyl- beta-D-glucose (PGG) for the chemoprevention of prostate cancer (PCa), the number 2 cause of cancer death in US men...
  13. Preclinical Development of JS-K, a Novel NO-Generating Prodrug for Cancer
    Paul J Shami; Fiscal Year: 2012
    ..In mouse xenograft models of human tumors, JS-K is highly effective against acute myeloid leukemia, prostate cancer, hepatocellular carcinoma, multiple myeloma and non-small cell lung cancer...
  14. Phage Display for Improved Peptide-based Tumor Targeting and Imaging Agents
    Susan L Deutscher; Fiscal Year: 2013
    ..Over 28% of cancer diagnoses in US Veterans in 2009 were for prostate, breast, and ovarian carcinoma. However, these cancers are often asymptomatic in beginning stages of the disease...
  15. FOXP3-microRNA146-NFkB Axis in Tumor Suppression
    Lizhong Wang; Fiscal Year: 2013
    ..More recently, we reported that FOXP3 suppresses prostate cancer by repressing transcription of c-MYC...
  16. FOLLOW UP OF THE ALPHA-TOCOPHEROL, BETA-CAROTENE CANCER PREVENTION (ATBC) STUDY
    Jarmo Virtamo; Fiscal Year: 2010
    ..Current cumulative totals of diagnosed cases through 2005 include approximately 2,800 lung, 2,000 prostate, 700 colorectal, 500 bladder, 300-400 each for stomach, pancreas, and kidney cancers, 300 head and neck, and 1,..
  17. Bioflavonoid Effects on EGF Signaling and Cell Cycle Pathways in Prostate Cancer
    BARRY MATTHEW MARKAVERICH; Fiscal Year: 2013
    ..interact with type II [3H]estradiol binding sites with high affinity (Kd" 5nM) and inhibit normal and malignant prostate cell proliferation in vivo and in vitro...
  18. MECHANISMS OF RADIORESISTANCE AND CELL CYCLE PROGRESSION
    Howard B Lieberman; Fiscal Year: 2013
    ..For examples, too much protein can cause apoptosis or lead to prostate cancer...
  19. Genistein and Prostate Cancer
    Rajvir Dahiya; Fiscal Year: 2010
    DESCRIPTION (provided by applicant): The main goal of this proposal is to investigate whether genistein inhibits prostate cancer growth through epigenetic pathways...
  20. Mechanistic Studies on Prostate Cancer Prevention by Gugulipid
    Dong Xiao; Fiscal Year: 2013
    DESCRIPTION (provided by applicant): Prostate cancer, a leading cause of cancer related deaths among men in the United States, is usually diagnosed in the sixth or seventh decades of life, which allows a large window of opportunity for ..
  21. Folate and S-adenosyimethionine in Methyl Group and One-carbon Metabolism
    Conrad Wagner; Fiscal Year: 2012
    ..are connected by the enzyme, glycine N-methyltransferase, which is abundant in liver, exocrine pancreas and prostate as well as in kidney and intestinal mucosa in lower amounts...
  22. Alcohol, Proteasome Dysfunction in Liver Injury
    Craig J McClain; Fiscal Year: 2013
    ..Thus, the prognosis for this disease is more ominous than for many common types of cancer such as breast, prostate, and colon...
  23. The Role of Adipocyte-Induced Inflammation in Prostate Tumor Progression
    AIMALIE LYNNETTE HARDAWAY; Fiscal Year: 2012
    DESCRIPTION (provided by applicant): Bone is a primary site of metastasis from prostate cancer (PCa) and most patients with advanced PCa experience complications from the bone lesions that are incurable...
  24. Mechanism of Age-Related Change in Estrogen Receptor Beta Expression in Rat Brain
    JENNE MITCHELL WESTBERRY; Fiscal Year: 2012
    ..Examples of epigenetic regulation of ER2 are seen in breast and prostate cancer where ER2 expression has been correlated with changes in methylation...
  25. PROSPECTIVE STUDIES OF DIET AND CANCER IN MEN AND WOMEN
    Walter C Willett; Fiscal Year: 2010
    ..collected dietary data, frozen plasma and DNA, and tumor tissue to address hypotheses regarding cancers of the prostate, colon and rectum, breast, and brain (glioma)...
  26. Beta 2-Microglobulin signaling and targeting in bone metastasis
    Leland W K Chung; Fiscal Year: 2013
    ..on the development of anti-b2-Microglobulin (b2-M) antibody as a therapeutic agent for the treatment of human prostate cancer bone metastasis...
  27. Amelioration of cisplatin ototoxicity by transplatin
    Debashree Mukherjea; Fiscal Year: 2010
    ..Importantly, transplatin did not inhibit the killing of prostate cancer cells by cisplatin...
  28. Ibis T-6,000 Biosensor System
    CYNTHIA SEARS; Fiscal Year: 2010
    ..of the structure of the fecal, respiratory or tissue microbiome in inflammatory bowel disease, colon and prostate cancer, progression of liver disease and transplant recipients with rejection and idiopathic lung diseases;2) ..
  29. Neuropilin and semaphorin, anti-angiogenesis activities and mechanisms
    Michael Klagsbrun; Fiscal Year: 2009
    ..Ids are upregulated in tumor EC isolated from the mouse TRAMP model of prostate carcinoma, suggesting that Ids are pro-angiogenic in vivo in spontaneous tumors...
  30. Parental age at birth and risk of adult-onset cancer in female offspring
    Yani Lu; Fiscal Year: 2013
    ..To date, the association with parental age has only been studied for breast cancer, prostate cancer and hematological malignancies...
  31. MicroRNAs in the Progression and Metastisis of Prostate Cancer
    Rajvir Dahiya; Fiscal Year: 2013
    DESCRIPTION (provided by applicant): MicroRNAs in the progression of prostate cancer. The main goal of this project is to investigate the role of a set of microRNAs (miRNAs) in the progression of prostate cancer...
  32. MECHANISM OF DRUG TRANSPORT IN LUNG CANCER CELLS
    Sanjay Awasthi; Fiscal Year: 2011
    ..conjugate (GS-E) transporter which is overexpressed in a number of types of cancers (lung, ovary, prostate, skin), but not in all types (breast, liver)...
  33. Sex-Hormones and the TMPRSS2: ERG Fusion in Prostate Cancer Progression
    Lorelei Mucci; Fiscal Year: 2013
    DESCRIPTION (provided by applicant): We propose to assess the impact of sex-steroid hormones and prostate cancer (PCa) progression in the context of the recently identified TMPRSS2:ERG translocation, a novel gene fusion of the 5'-..
  34. Genomic Enhancers at 8q24 and Prostate Cancer
    Gerhard A Coetzee; Fiscal Year: 2013
    DESCRIPTION (provided by applicant): Genomic Enhancers at 8q24 and Prostate Cancer The understanding of genetic predisposition to prostate cancer (PCa) and the identification of at-risk alleles have undergone a revolution during the past ..
  35. Roles of RhoA/Rho-kinase Signaling in Cavernous Neurons Following Axonal Injury
    TRINITY JUDE BIVALACQUA; Fiscal Year: 2013
    ..b>Prostate cancer is the most commonly diagnosed cancer in the United States...
  36. Iron, NO, and Lipid Peroxide in Photodynamic Therapy
    ALBERT GIROTTI; Fiscal Year: 2013
    ..Our overall plan for testing this hypothesis is to study: (i) relative abilities of various established breast, prostate, and skin carcinoma cells to overexpress cytoprotective NOS/NO under ALA/light stress;(ii) mechanisms of NOS ..
  37. Robot-Assisted MRI-Guided Prostate Biopsy
    Dan Stoianovici; Fiscal Year: 2010
    ..and target area (1) Improving the accuracy of biopsy sampling/staging of disease such as in the evaluation for prostate cancer, with a new instrument for MRI-guided prostate biopsy...
  38. Arsenic, Histone Modification, and Transcription
    LYNN SHELDON; Fiscal Year: 2009
    Long term exposure to low levels of arsenic is associated with multiple diseases including skin, lung, liver, and prostate cancers, as well as metabolic disorders including hypertension and diabetes...
  39. Developing a murine model for arsenic-induced skin neoplasm
    Mohammad Athar; Fiscal Year: 2010
    ..of the lung, skin (both basal cell carcinomas (BCCs) and squamous cell carcinomas (SCCs)), bladder, liver, prostate as well as in other organs...
  40. The influence of selenium on biomarkers of prostate cancer risk
    KARAM E EL-BAYOUMY; Fiscal Year: 2012
    DESCRIPTION (provided by applicant): In the USA, prostate cancer (PC) is the second leading cause of cancer-related death in men;aging is a major risk factor and African Americans (AA) are at a higher risk than white Americans (WA)...
  41. Modulation of cancer prevention by social stress
    Hildegard M Schuller; Fiscal Year: 2010
    ..of PAC and PDAC prevention and also provide a foundation for improved prevention of cancer of the colon, prostate, breast, stomach and ovary, all of which are stimulated by beta-adrenergic signaling...
  42. Endothelin-1 and androgen in prostate cancer bone metastasis and bone health
    Gregory A Clines; Fiscal Year: 2013
    ..also a tumor-secreted factor that has a central role in osteoblast activation and the osteosclerotic response of prostate cancer metastatic to bone...
  43. Role of the insulin/IGF-axis in incident CIN-2+
    Howard D Strickler; Fiscal Year: 2010
    ..IGF-axis protein levels are associated with the risk of several solid tumors, including tumors of the breast and prostate. Little is known, however, regarding the IGF-axis's relation with cervical cancer, the second most common ..
  44. Biomarker Reference Laboratory, EDRN
    William E Grizzle; Fiscal Year: 2010
    ..use of SELDI-TOF-MS to identify protein signatures in serum that predict the presence of adenocarcinoma of the prostate. A developmental project is proposed in which the effects of fixatives and antigen retrieval techniques on real ..
  45. Combined use of green tea and quercetin in prostate cancer
    SUSANNE MARGARETE HENNING; Fiscal Year: 2012
    ..We determined that 50 percent or more of GTPs in human prostate tissue and urine is found in methylated form and that methylation significantly decreased the anticarcinogenic ..
  46. Amoeboid Membrane Dynamics in Prostate Cancer
    Michael R Freeman; Fiscal Year: 2013
    DESCRIPTION (provided by applicant): Prostate adenocarcinoma (PCa) is a leading cause of death from cancer and there is no effective treatment for "castration-resistant" disease...
  47. ROLE OF COREGULATORS IN STEROID HORMONE-REGULATED TRANSCRIPTION
    Michael R Stallcup; Fiscal Year: 2013
    ..the information necessary to assess whether coregulators are reasonable targets for intervention in breast and prostate cancer and in other steroid hormone-related diseases...
  48. HIFU-enhanced tumor vaccines
    Chandan Guha; Fiscal Year: 2012
    ..has demonstrated that HIFU induces coagulative necrosis in tumor tissues and controls tumor growth of localized prostate, renal cell and liver cancers...
  49. Neuronal mRNA PET Imaging
    Eric Wickstrom; Fiscal Year: 2010
    ..KRAS mRNAs have enabled us to visualize gene expression in live mice bearing breast cancer, pancreas cancer, and prostate cancer xenografts. Mismatch probes and control cells yielded background signals...
  50. Prostate cancer prevention by selenium supplementation
    Rayudu Gopalakrishna; Fiscal Year: 2012
    ..In preneoplastic prostate cells, a low amount of methylselenol, a volatile selenometabolite, reacts with tumor-promoting peroxides and is ..
  51. Characterizing gene regulation with single molecule sensitive probes
    Philip J Santangelo; Fiscal Year: 2013
    ..through the development of this technology, we will be able to characterize these events in cellular models of prostate tumor progression, both fixed and live, and in clinical tumor samples...
  52. Inhibition of S14 by Conjugated Linoleic Acid in Advanced Solid Tumor Patients
    Raymond P Perez; Fiscal Year: 2010
    ..new approach to cancer therapy - one with the potential to benefit patients with many common cancers (breast, prostate, lung, ovarian, and some leukemias)...
  53. Underserved Men's Understanding of Androgen Deprivation Therapy Related Risks
    Sally L Maliski; Fiscal Year: 2012
    DESCRIPTION (provided by applicant): Androgen deprivation therapy (ADT) is increasingly being used to treat prostate cancer in the neoadjuvant and adjuvant contexts with radiation therapy (RT), for recurrence following primary treatment ..
  54. TRANSCRIPTIONAL REPRESSION BY POLYCOMB GROUP PRODUCTS
    Jeffrey A Simon; Fiscal Year: 2012
    ..Overabundance of PcG proteins is also implicated in disease progression in cancers of the breast, prostate, and other tissues...
  55. Androgen Receptor-JunD Complex Inhibitors to Prevent Prostate Cancer Progression
    Hirak S Basu; Fiscal Year: 2012
    ..Therefore, the development of new and effective therapies to treat early-stage prostate cancer (PCa) to prevent progression of PCa to CRPCa is warranted. Our collaborator Dr...
  56. Role of Id1 in NSCLC Progression and Metastasis
    Srikumar P Chellappan; Fiscal Year: 2013
    ..to play a significant role in the progression and metastasis of a variety of tumors, including those of breast, prostate and pancreas;at the same time, little is known about its potential role in the biology of NSCLC...
  57. Detection of Prostate Cancer Genomic Signatures in Blood
    Amin I Kassis; Fiscal Year: 2010
    ..The diagnosis of prostate cancer (PC) is usually subsequent to routine prostate-specific antigen (PSA) determination in blood and/or ..
  58. Targeting ATAP-mediated Apoptosis in Treatment of Prostate Cancer
    Zelin Sheng; Fiscal Year: 2013
    ..Moreover, ATAP-iRGD was effective at inducing cell death in the DU145 human prostate cancer cell line that was resistant to the effects of BH3 peptide therapy...
  59. A Molecular targeting agent for systemic radiotherapy of metastatic Prostate Canc
    Kevin P Maresca; Fiscal Year: 2010
    ..by applicant): Currently, there are no effective therapies for relapsing, metastatic or androgen-independent prostate cancers;appropriate intervention would be greatly enhanced with specific monitoring of wide spread micro-disease...
  60. CHEMISTRY SUPPORT SERVICES TO THE ENVIRONMENTAL TOXICOLOGY PROGRAM
    CLARK ALGAIER; Fiscal Year: 2009
    ..monooxygenase (PAM) activity in soluble and membrane fractions of 4-phenyl-3-butenoic acid (PBA) treated prostate cancer cell (PC-3) lysates...
  61. PKC/PKA Regulation in Prostate Cancer by SSeCKS/Gravin/AKAP12
    Irwin H Gelman; Fiscal Year: 2013
    ..In human prostate cancer (CaP), PKC, levels increase with malignancy whereas PKC* levels are constant, yet only the overexpression ..
  62. PTH-RELATED PEPTIDE AND VIT D IN PROSTATE CANCER GROWTH
    Miriam Falzon; Fiscal Year: 2009
    DESCRIPTION (provided by applicant): Prostate cancer is the largest cause of male cancer death in the United States;many prostate cancer patients have metastatic disease at diagnosis...
  63. Timing of Exposure to Selenium and Isoflavones and Prostate Cancer Prevention
    EDWIN DOUGLAS LEPHART; Fiscal Year: 2010
    ..applicant): The research described in this AREA application is responsive to recommendations in the Report of the Prostate Cancer Progress Review Group (PRG)...
  64. DNA methylation in aging, race and prostate cancer
    Rajvir Dahiya; Fiscal Year: 2006
    ..proposal is to identify and characterize the epigenetic alterations that are involved in aging and race-related prostate cancer...
  65. Gene Networks for Prostate Cancer Progression
    Leif Peterson; Fiscal Year: 2005
    Background: Prostate cancer is the most common and leading cause of cancer death among U.S. males...
  66. Selection and Characterization of PSMA Ligands from Phage-Displayed Libraries
    Gary Fujii; Fiscal Year: 2006
    unreadable] DESCRIPTION (provided by applicant): Prostate Specific Membrane Antigen (PSMA) is a marker in prostate tumors and solid tumor neovasculature that has recently become a focus for anti-cancer therapies...
  67. Ultrasound guided site-specific gene delivery in prostate cancer
    Pier Paolo Claudio; Fiscal Year: 2010
    This proposal aims at improving the efficiency and specificity of gene delivery in prostate cancer (PC) by using an innovative system consisting of ultrasound contrast agents, viral vectors and ultrasound waves...
  68. Biomarker Prediction of Gleason Upgrading
    Bruce J Trock; Fiscal Year: 2010
    DESCRIPTION (provided by applicant): The success of the current paradigm of PSA screening and prostate cancer treatment, while contributing to a reduction in mortality, has also led to the problems of over diagnosis and over treatment...
  69. Pilot trial of a DNA vaccine encoding PAP in patients with prostate cancer
    Douglas McNeel; Fiscal Year: 2009
    DESCRIPTION (provided by applicant): Prostate cancer is a significant worldwide health problem for which new treatments are needed...
  70. Decision Making in Unaffected First-Degree Relatives of Prostate Cancer Patients
    Clement Gwede; Fiscal Year: 2009
    DESCRIPTION (provided by applicant): The use of the prostate specific antigen (PSA) test in the general population and identifiable high-risk subgroups remains controversial, and the PSA test remains the only available test to date to ..
  71. Modular internalizing molecules for treatment of more than one stage of malignanc
    Michael Lawrence Greenberg; Fiscal Year: 2010
    ..b>Prostate cancer is the most common form of cancer and the second leading cause of death among men in the United States...
  72. Effectiveness of Early Stage Prostate Cancer Treatment
    MARTIN G contact SANDA; Fiscal Year: 2010
    ..Effectiveness of prostate cancer treatment has been previously evaluated by Markov models to measure Quality-adjusted Life Expectancy (QALE)..
  73. Proximal Prostate Fluids for Protein and miRNA Biomarkers
    Richard R Drake; Fiscal Year: 2010
    Detection of prostate specific antigen (PSA) levels in serum as a biomarker of prostate cancer continues to evolve to reflect new knowledge about disease-specific isoforms and free versus bound complexes with serum proteins...
  74. Fabrication and validation of implantable MRI markers for prostate cancer treatme
    Andrew Bright; Fiscal Year: 2010
    DESCRIPTION (provided by applicant): Approximately 60,000 of the 200,000 men diagnosed annually with prostate cancer are treated with brachytherapy. Prostate brachytherapy (PB) is performed using tiny radioactive (0...
  75. Prostate MRI and MRS: Correlations with Gene Expression
    Sandra Gaston; Fiscal Year: 2007
    ..Imaging (MRI) is a rapidly developing noninvasive technology that is under evaluation as a tool for determining prostate cancer location, stage and grade in patients with clinically organ confined disease...
  76. Communication and Chemoprevention of Prostate Cancer
    Parmender Mehta; Fiscal Year: 2009
    The role of cell contact-dependent communication in the progression of prostate cancer from a slow-growing hormone (androgen)-dependent state to a highly malignant, hormone-independent state is not fully understood...
  77. Development of a combination therapy for the treatment of prostate cancer
    FRANCIS MARKLAND; Fiscal Year: 2007
    unreadable] DESCRIPTION (provided by applicant): Prostate cancer (PC) is the second most common form of cancer in American males, second only to skin cancer. In addition, it trails only lung cancer as a cause of death from cancer...
  78. Mouse Models of ErbB-2 and Cyclin D1 in Prostate Cancer
    Christopher Albanese; Fiscal Year: 2002
    ..we aim to directly determine the role of ErbB-2 and cyclin D1 in cellular proliferation and transformation in prostate cancer cells. Both ErbB-2 and cyclin D1 are frequently over-expressed in prostate, breast and colon cancer...